Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 19, 2026, 5:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 41 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Injectable clostridial collagenase Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Efficacy and Safety of Xiaflex Injection for Treatment of Dupuytren's Contracture of the Thumb

NCT01265420
View directory record Official record
Conditions
Dupuytren's Contracture
Interventions
Injectable clostridial collagenase
Biological
Lead sponsor
Indiana Hand to Shoulder Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Indianaplis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 29, 2015 · Synced Sep 19, 2026, 5:49 AM EDT
Completed Phase 3 Interventional Results available

AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Dupuytren's Contracture

NCT00528606
View directory record Official record
Conditions
Dupuytren's Contracture
Interventions
collagenase clostridium histolyticum, Placebo
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
15
States / cities
Los Angeles, California • Palo Alto, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2017 · Synced Sep 19, 2026, 5:49 AM EDT
Completed Phase 2 Interventional Results available

Pharmacokinetics of a Single Treatment Cycle of AA4500 0.58 mg in Men With Peyronie's Disease

NCT01430169
View directory record Official record
Conditions
Peyronie's Disease
Interventions
AA4500
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Burbank, California
Source: ClinicalTrials.gov public record
Updated Oct 4, 2017 · Synced Sep 19, 2026, 5:49 AM EDT
Completed Phase 2 Interventional Results available

The Safety and Effectiveness of AA4500 in Subjects With Peyronie's Disease

NCT00755222
View directory record Official record
Conditions
Peyronie's Disease
Interventions
AA4500, Placebo
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
12
States / cities
Burbank, California • Middlebury, Connecticut • New Haven, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2017 · Synced Sep 19, 2026, 5:49 AM EDT
Completed Phase 2 Interventional Results available

Phase 2a Dose-Ranging Study to Evaluate Safety and Effectiveness of AA4500 in Treatment of Dupuytren's Disease Nodules

NCT02193828
View directory record Official record
Conditions
Dupuytren's Disease
Interventions
Collagenase clostridium histolyticum, Placebo
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
9
States / cities
Tucson, Arizona • Encinitas, California • Greenbrae, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2017 · Synced Sep 19, 2026, 5:49 AM EDT
Completed Phase 3 Interventional Results available

Collagenase in the Treatment of Dupuytrens Disease

NCT00260429
View directory record Official record
Conditions
Dupuytren's Disease
Interventions
collagenase clostridium histolyticum
Biological
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Dec 8, 2010 · Synced Sep 19, 2026, 5:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Pharmacokinetics of a Single Dose of CCH (3.36 mg) in Subjects With EFP

NCT03675685
View directory record Official record
Conditions
Edematous Fibrosclerotic Panniculopathy
Interventions
CCH (collagenase clostridium histolyticum)
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Sep 19, 2026, 5:49 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Double Blind Study to Evaluate the Efficacy of Collagenase Histolyticum in the Treatment of Lipoma

NCT02249052
View directory record Official record
Conditions
Lipoma
Interventions
AA4500, placebo
Drug
Lead sponsor
Gerut, Zachary, M.D.
Individual
Eligibility
18 Years to 75 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
2
States / cities
Hewlett, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 22, 2017 · Synced Sep 19, 2026, 5:49 AM EDT
Recruiting Not applicable Interventional

Concurrent Low Intensity Shockwave Therapy on Collagenase Clostridium Histolyticum for Peyronie's Disease

NCT06065436
View directory record Official record
Conditions
Peyronie Disease, Erectile Dysfunction
Interventions
Collagenase Clostridium Histolyticum, Storz Duolith LiSWT
Drug · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 19, 2026, 5:49 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Effectiveness of Splinting After Collagenase Injection

NCT04874870
View directory record Official record
Conditions
Dupuytren Contracture, Dupuytren's Disease
Interventions
Collagenase Clostridium Histolyticum 0.9 MG [Xiaflex], Xiaflex + Hand-Based Custom Orthosis
Drug · Combination Product
Lead sponsor
Foundation for Orthopaedic Research and Education
Other
Eligibility
18 Years to 90 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 25, 2025 · Synced Sep 19, 2026, 5:49 AM EDT
Completed Phase 3 Interventional Results available

A Study of AA4500 in Men With Peyronie's Disease

NCT01243411
View directory record Official record
Conditions
Peyronie's Disease
Interventions
AA4500
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
13
States / cities
Burbank, California • Middlebury, Connecticut • New Haven, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2017 · Synced Sep 19, 2026, 5:49 AM EDT
Completed Phase 3 Interventional Results available

Administration of Two Injections for Multiple Dupuytren's Contractures

NCT01407068
View directory record Official record
Conditions
Dupuytren's Contracture
Interventions
AA4500 collagenase clostridium histolyticum
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
4
States / cities
Tucson, Arizona • Indianapolis, Indiana • Stony Brook, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2017 · Synced Sep 19, 2026, 5:49 AM EDT
Completed Phase 4 Interventional Results available

Retreatment of Recurrent Dupuytren's Contractures

NCT01498640
View directory record Official record
Conditions
Dupuytren's Disease
Interventions
Collagenase clostridium histolyticum
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
7
States / cities
Phoenix, Arizona • Rockford, Illinois • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2017 · Synced Sep 19, 2026, 5:49 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Effect of Oral TXA on Buttock Bruising Post CCH Injections in Adult Females

NCT05309525
View directory record Official record
Conditions
Cellulite
Interventions
Collagenase Clostridium Histolyticum-Aaes, Lysteda 650 MG Oral Tablet
Drug
Lead sponsor
Luxurgery
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 7, 2023 · Synced Sep 19, 2026, 5:49 AM EDT
Completed Phase 2 Interventional Results available

AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder

NCT01483963
View directory record Official record
Conditions
Adhesive Capsulitis, Frozen Shoulder
Interventions
AA4500 0.29 mg/1 mL, AA4500 0.58 mg/2 mL, AA4500 0.58 mg/1 mL, AA4500 0.58 mg/0.5 mL, Shoulder exercises
Biological · Other
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
15
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2017 · Synced Sep 19, 2026, 5:49 AM EDT
Active, not recruiting Phase 4 Interventional

Delayed Dose Collagenase Clostridium Histolyticum (CCH) Protocol for Men With Peyronie's Disease

NCT06649539
View directory record Official record
Conditions
Peyronie Disease
Interventions
Collagenase Clostridium Histolyticum, RestoreX, Sildenafil
Drug · Device
Lead sponsor
Charitable Union for the Research and Education of Peyronie's Disease
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Orem, Utah
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 19, 2026, 5:49 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Histopathology Following CCH Injection

NCT04236635
View directory record Official record
Conditions
Characteristics of Subcutaneous Tissue
Interventions
Collagenase Clostridium Histolyticum Single Injection Technique, Collagenase Clostridium Histolyticum Multiple Injection Technique
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Montclair, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 11, 2022 · Synced Sep 19, 2026, 5:49 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Delayed Manipulation After Xiaflex Treatment in Subjects With Dupuytren's Contracture

NCT01226121
View directory record Official record
Conditions
Dupuytren's Disease
Interventions
Clostridial collagenase injectable
Biological
Lead sponsor
Indiana Hand to Shoulder Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
2
States / cities
Indianaplis, Indiana • Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Jun 15, 2014 · Synced Sep 19, 2026, 5:49 AM EDT
Completed Phase 2 Interventional Results available

A Dose Escalation Study Using Collagenase Clostridium Histolyticum in the Treatment of Lipoma

NCT01613313
View directory record Official record
Conditions
Lipoma
Interventions
Collagenase Clostridium Histolyticum
Drug
Lead sponsor
Zachary Gerut
Individual
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Hewlett, New York
Source: ClinicalTrials.gov public record
Updated Oct 5, 2016 · Synced Sep 19, 2026, 5:49 AM EDT
Completed Phase 2 Interventional

A Study to Assess Collagenase Clostridium Histolyticum (CCH) in the Treatment of Plantar Fasciitis (PFA)

NCT06169319
View directory record Official record
Conditions
Plantar Fasciitis
Interventions
Collagenase Clostridium Histolyticum (CCH), Placebo
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
39
States / cities
Tucson, Arizona • Castro Valley, California • Corona, California + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Sep 19, 2026, 5:49 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

To Assess the Effectiveness of Multiple Dose, Multiple Concentrations of Qwo, for the Treatment of Mild to Moderate Cellulite.

NCT05026216
View directory record Official record
Conditions
Cellulite
Interventions
Qwo
Drug
Lead sponsor
DMR Research, PLLC
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Westport, Connecticut
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Sep 19, 2026, 5:49 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Injection Techniques of Collagenase Clostridium Histolyticum (CCH) for the Treatment of EFP (Cellulite)

NCT03632993
View directory record Official record
Conditions
Edematous Skin
Interventions
collagenase clostridium histolyticum (CCH)
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
5
States / cities
Coral Gables, Florida • Miami, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Sep 19, 2026, 5:49 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Investigation of Surgery, Collagenase, and Restorex for the Improvement of Peyronie's

NCT04786106
View directory record Official record
Conditions
Peyronie's Disease
Interventions
Collagenase Clostridium Histolyticum 0.9 MG [Xiaflex] (CCH), Penile Plication Surgery, Incision and Grafting (I&G) Surgery, RestoreX Penile Traction Device
Drug · Procedure · Device
Lead sponsor
Charitable Union for the Research and Education of Peyronie's Disease
Other
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
1
States / cities
Orem, Utah
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 19, 2026, 5:49 AM EDT
Withdrawn Not applicable Interventional

Focused Shock Wave Therapy Outcomes in Peyronie's Disease and Erectile Dysfunction

NCT05646602
View directory record Official record
Conditions
Peyronie Disease, Penile Curvature, Erectile Dysfunction
Interventions
Collagenase Clostridium Histolyticum, Duolith SD1 T-TOP
Drug · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 9, 2023 · Synced Sep 19, 2026, 5:49 AM EDT